We're dedicated to your pup's health! Click below to learn why WayPath is different.
We're dedicated to your pup's health! Click below to learn why WayPath is different.
Compounds Synthesized
Intellectual property protecting our novel compounds
New GBM Cases/Year (US)
WayPath Pharma in the News
Press Release
- September 2022 awarded STTR Phase 1 grant from the NIH
- November 2025 Submitted Phase II
WayPath's foundational research advanced from compound formulation through pre-clinical testing to a canine pilot study with compelling efficacy data. A pilot study in a canine diagnosed with Hemangiosarcoma (HSA) demonstrated a 26-month life extension following daily oral administration — far exceeding the 2-week median survival expected without treatment.
WayPath is led by world-class experts in oncology, medicinal chemistry, and drug development. Dr. Krzysztof Reiss co-founded the company following the successful treatment of his own canine companion diagnosed with HSA. A breakthrough that validated the compound's therapeutic potential. Dr. Reiss has authored over 165 peer-reviewed publications spanning cell signaling, energy metabolism, DNA repair, oncogenic viruses, and brain tumor models.
WayPath is seeking strategic partners and investors to advance its pipeline through critical milestones:
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.